Publication | Closed Access
Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results
307
Citations
24
References
2003
Year
CA4P was well tolerated in 14 of 16 patients at 52 or 68 mg/m2; these are doses at which tumor blood flow reduction has been recorded.
| Year | Citations | |
|---|---|---|
Page 1
Page 1